Participated · Equity · Apr 2021

Nestwave provides low-power geolocation IP and cloud services purpose-built for Internet of Things (IoT) applications, using hybrid GNSS and cellular positioning technologies. Its DSP software enables IoT modem and wireless MCU chipmakers to integrate accurate positioning for LTE Cat M1, NB‑IoT, LoRa and Sigfox platforms without a dedicated positioning chipset. The solution significantly reduces power consumption compared with traditional GNSS offerings, improves accuracy in urban canyon environments and increases indoor coverage. Nestwave’s technology is supported by more than 10 patents issued and pending. The company says the new capital will accelerate technology innovation, product development and commercial deployment of its positioning solutions. Nestwave is based in Paris, France. Nestwave develops a DSP software GNSS solution that enables modem providers in the IoT market (LTE Cat M1, NB-IoT, LoRa, Sigfox) to offer accurate, integrated geolocation. The technology is built on 10 issued and pending patents and is designed to improve accuracy in urban canyon environments, increase indoor coverage, and reduce power consumption versus existing solutions. The company targets integration within modem platforms to deliver location services for IoT applications. Nestwave plans to use new funding to carry out its product innovation strategy, accelerate development and intensify commercial deployment. Founded in 2014 by Rabih Chrabieh and based in Paris, France, the company is focused on scaling its commercial footprint in target IoT markets. The article does not report operating metrics such as revenue or user counts.

Participated · Series A · Feb 2021

AcuSurgical, founded in 2020 and based in Montpellier, France, is developing a telemanipulated robotic platform for ocular microsurgery with an initial focus on vitreo‑retinal procedures. The platform is designed to filter surgeon tremor, augment visualization, and keep the surgeon in full control to increase precision and reproducibility of complex retinal surgeries. A proof of concept has been completed and a first prototype was validated in a preclinical setting. The company will use the Series A proceeds to conduct clinical trials and pursue regulatory approval for vitreo‑retinal indications, with plans to expand to additional ophthalmic applications thereafter. AcuSurgical cites a worldwide patient population of more than 300 million with retinal disease and notes 1.6 million retinal surgeries performed annually, representing a growing market. The €5.75 million Series A is intended to grow the team and fund milestones toward certification and commercialization.

Participated · Equity · Sep 2020

Antaios develops Spin-Orbit Torque Magnetic Random-Access Memory (SOT-MRAM), a next-generation MRAM technology that combines high operating speed with effectively infinite read/write endurance. The technology draws on a decade of research at SPINTEC and is positioned to help chip manufacturers address power demands in advanced semiconductor systems. SOT-MRAM has the potential to replace embedded non-volatile memory (e.g., NOR-Flash) and embedded cache (e.g., SRAM) in microcontrollers, microprocessors and SoC designs. It can be implemented on existing STT-MRAM manufacturing lines, supporting faster market deployment across IoT, mobile, computing and storage applications. Founded in 2017 and led by CEO Jean-Pierre Nozières, Antaios is based in Grenoble, France. In 2020 the company secured $11M in funding to develop new strategic partnerships.

Participated · Series A · Jul 2020

deepull is a Barcelona, Spain-based medical diagnostics company focused on culture-free diagnostic solutions for sepsis and acute infections. It is developing the UllCORE BSI Test, an automated, walkaway system that uses molecular techniques to extract and detect microbial DNA directly from whole blood. The multiplex PCR test covers 95% of sepsis-causing pathogens, including bacteria and fungi, and detects antibiotic resistance genes, providing critical results in about one hour. deepull intends to use the €50M Series C proceeds to finalize clinical validation and expedite regulatory approval of its UllCORE diagnostic system. The company is led by CEO Jordi Carrera. The Series C included participation from multiple existing investors alongside the new lead investors. DeepUll is a medical technology company developing culture-free diagnostics for early identification of sepsis and other acute infections. Founded in 2020 in Barcelona by the founders of STAT-Dx, the company has assembled a team of globally recognized experts. Its sepsis product is designed to detect more than 250 pathogens and 15 resistance genes from 10 mL of blood in about one hour. The product also generates phenotypic antimicrobial susceptibility results in roughly eight hours without requiring a positive blood culture. Intended as a desktop, end-to-end automated device, it is designed for deployment in laboratories, emergency departments and ICUs. The company aims to improve patient outcomes and reduce unnecessary antimicrobial use; the recent Series B financing that reached €17M will support platform development and the path to market. DeepUll develops culture-free, affordable diagnostic solutions aimed at the early identification of sepsis and other acute infections. Its core product is an automated, desktop diagnostics platform designed to detect more than 250 pathogens and about 15 resistance genes in one hour from 10 mL of whole blood. The system produces phenotypic antimicrobial-susceptibility results in about eight hours without requiring a positive blood culture and is intended for deployment in laboratories, emergency rooms and ICUs. DeepUll’s platform includes end-to-end automation and leverages artificial intelligence to provide medical decision support across early recognition, precise diagnostics and therapy guidance. To accelerate development, DeepUll will expand its RD&I activities to bring the automated diagnostics device toward clinical use. The company was founded in 2020 in Barcelona by the founders of STAT-Dx. DeepUll develops culture-free diagnostic solutions for sepsis and acute infections. Its sepsis product is designed to detect more than 250 different pathogens and about 15 resistance genes in one hour starting from 10mL of whole blood. The product will generate phenotypic antimicrobial susceptibility results in about eight hours, without requiring a positive blood culture. It is planned as a desktop system with end-to-end automation, intended to be placed in any clinical setting. The company raised €13M in a Series B to progress the development of its sepsis recognition platform toward the market. DeepUll was founded by Jordi Carrera and Rafel Bru, who previously co-founded STAT-Dx (acquired by Qiagen in 2018), and is based in Barcelona, Spain. DeepUll is building a diagnostic platform that identifies pathogens and provides antibiograms in a few hours without prior culture, and incorporates patient immunological status and AI to predict sepsis onset and evolution. The system aims to enable earlier, precision therapeutic recommendations by combining pathogen detection with data-driven assessment of the patient’s immune and functional status. The company plans to validate the underlying technologies and build initial diagnostic units to demonstrate clinical utility. The funds raised in the announced round are intended to cover the financial needs for technology validation and the development of first devices. DeepUll was founded in 2019 by Jordi Carrera and Rafel Bru and is based in the Parc Científic de Barcelona. The team highlights prior entrepreneurial experience from selling STAT-Dx to QIAGEN and positions the product to address sepsis and antibiotic resistance at hospital scale.

Participated · Series A · Mar 2019

Igyxos is developing a first-in-class monoclonal antibody designed to potentiate the bioactivity of endogenous and exogenous gonadotropins to improve therapeutic management of male and female infertility. The company is led by CEO Pierre-Henry Longeray and founder/CSO Marie-Christine Maurel. It is based in Nouzilly, France. Igyxos raised €7.5m in a Series A round and intends to use the funds to finance development of its drug candidate until proof of concept in human clinic. Backers named in the financing include Bpifrance (via the Accelerate Biotechnologies Santé Fund under the Investments for the Future Program), Go Capital’s Amorçage II and Loire Valley Invest funds, and the Fonds Emergence Innovation II managed by Sofimac Innovation. The company’s immediate plan is to advance its monoclonal antibody program toward human proof of concept.